Nephro-Urology Monthly

Published by: Kowsar

Recent Strategies for the Management of Renal Angiomyolipoma: A Review of Diagnostic and Therapeutic Approaches

Alireza Akhavan Rezayat 1 , Mohammad Aslezare 1 , Hassan Ahmadnia 1 , Salman Soltani 1 and Amirabbas Asadpour 1 , *
Authors Information
1 Department of Urology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Nephro-Urology Monthly: November 2017, 9 (6); e14251
  • Published Online: October 3, 2017
  • Article Type: Review Article
  • Received: May 29, 2017
  • Revised: July 14, 2017
  • Accepted: September 18, 2017
  • DOI: 10.5812/numonthly.14251

To Cite: Akhavan Rezayat A, Aslezare M, Ahmadnia H, Soltani S, Asadpour A. Recent Strategies for the Management of Renal Angiomyolipoma: A Review of Diagnostic and Therapeutic Approaches, Nephro-Urol Mon. 2017 ; 9(6):e14251. doi: 10.5812/numonthly.14251.

Copyright © 2017, Nephro-Urology Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Methods
3. Conclusions
  • 1. Martignoni G, Cheville J, Fletcher CDM. World health organization classification of tumours of the urinary system and male genital organs. 2016; : 62-5
  • 2. Stone CH, Lee MW, Amin MB, Yaziji H, Gown AM, Ro JY, et al. Renal angiomyolipoma: further immunophenotypic characterization of an expanding morphologic spectrum. Arch Pathol Lab Med. 2001; 125(6): 751-8[DOI][PubMed]
  • 3. Al Omran B, Ansari N. Aneurysm in a Large Sporadic Renal Angiomyolipoma. Oman Med J. 2016; 31(3): 223-6[DOI][PubMed]
  • 4. Lei JH, Liu LR, Wei Q, Song TR, Yang L, Yuan HC, et al. A Four-Year Follow-up Study of Renal Epithelioid Angiomyolipoma: A Multi-Center Experience and Literature Review. Sci Rep. 2015; 5: 10030[DOI][PubMed]
  • 5. Song X, Liu Z, Cappell K, Gregory C, Said Q, Prestifilippo J, et al. Healthcare utilization and costs in patients with tuberous sclerosiscomplex-related renal angiomyolipoma. J Med Econ. 2017; 20(4): 388-94[DOI]
  • 6. Laguna MP. Re: Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm can be Offered Active Surveillance as an Initial Management Strategy. J Urol. 2016; 196(5): 1397-8[DOI][PubMed]
  • 7. Rakowski SK, Winterkorn EB, Paul E, Steele DJ, Halpern EF, Thiele EA. Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors. Kidney Int. 2006; 70(10): 1777-82[DOI][PubMed]
  • 8. Kuusk T, Biancari F, Lane B, Tobert C, Campbell S, Rimon U, et al. Treatment of renal angiomyolipoma: pooled analysis of individual patient data. BMC Urol. 2015; 15: 123[DOI][PubMed]
  • 9. Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. J Urol. 2002; 168(4 Pt 1): 1315-25[DOI][PubMed]
  • 10. Sooriakumaran P, Gibbs P, Coughlin G, Attard V, Elmslie F, Kingswood C, et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int. 2010; 105(1): 101-6[DOI][PubMed]
  • 11. Eble JN. Angiomyolipoma of kidney. Semin Diagn Pathol. 1998; 15(1): 21-40[PubMed]
  • 12. Yamakado K, Tanaka N, Nakagawa T, Kobayashi S, Yanagawa M, Takeda K. Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology. 2002; 225(1): 78-82[DOI][PubMed]
  • 13. Kingswood JC, Doyle T, Cox J. The natural history of renal angiomyolipoma (AMLS) in tuberous sclerosis complex (TSC). 49th ERA-EDTA Congress. 2012;
  • 14. Bhatt JR, Richard PO, Kim NS, Finelli A, Manickavachagam K, Legere L, et al. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs >4cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol. 2016; 70(1): 85-90[DOI][PubMed]
  • 15. Nasri H. Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients. Cell J. 2014; 15(4): 378-80[PubMed]
  • 16. Smith SJ, Bosniak MA, Megibow AJ, Hulnick DH, Horii SC, Raghavendra BN. Renal cell carcinoma: earlier discovery and increased detection. Radiology. 1989; 170(3 Pt 1): 699-703[DOI][PubMed]
  • 17. Halpenny D, Snow A, McNeill G, Torreggiani WC. The radiological diagnosis and treatment of renal angiomyolipoma-current status. Clin Radiol. 2010; 65(2): 99-108[DOI][PubMed]
  • 18. Song S, Park BK, Park JJ. New radiologic classification of renal angiomyolipomas. Eur J Radiol. 2016; 85(10): 1835-42[DOI][PubMed]
  • 19. Simpson E, Patel U. Diagnosis of angiomyolipoma using computed tomography-region of interest < or =-10 HU or 4 adjacent pixels < or =-10 HU are recommended as the diagnostic thresholds. Clin Radiol. 2006; 61(5): 410-6[DOI][PubMed]
  • 20. Nikken JJ, Krestin GP. MRI of the kidney-state of the art. Eur Radiol. 2007; 17(11): 2780-93[DOI][PubMed]
  • 21. Kim JK, Kim SH, Jang YJ, Ahn H, Kim CS, Park H, et al. Renal angiomyolipoma with minimal fat: differentiation from other neoplasms at double-echo chemical shift FLASH MR imaging. Radiology. 2006; 239(1): 174-80[DOI][PubMed]
  • 22. Steiner MS, Goldman SM, Fishman EK, Marshall FF. The natural history of renal angiomyolipoma. J Urol. 1993; 150(6): 1782-6[DOI][PubMed]
  • 23. Jinzaki M, Silverman SG, Tanimoto A, Shinmoto H, Kuribayashi S. Angiomyolipomas that do not contain fat attenuation at unenhanced CT. Radiology. 2005; 234(1): 311[DOI][PubMed]
  • 24. Jeong CJ, Park BK, Park JJ, Kim CK. Unenhanced CT and MRI Parameters That Can Be Used to Reliably Predict Fat-Invisible Angiomyolipoma. AJR Am J Roentgenol. 2016; 206(2): 340-7[DOI][PubMed]
  • 25. Silverman SG, Israel GM, Herts BR, Richie JP. Management of the incidental renal mass. Radiology. 2008; 249(1): 16-31[DOI][PubMed]
  • 26. Brimo F, Robinson B, Guo C, Zhou M, Latour M, Epstein JI. Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol. 2010; 34(5): 715-22[DOI][PubMed]
  • 27. Cheng L, Gu J, Eble JN, Bostwick DG, Younger C, MacLennan GT, et al. Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas. Am J Surg Pathol. 2001; 25(10): 1231-6[DOI][PubMed]
  • 28. Tazelaar HD, Batts KP, Srigley JR. Primary extrapulmonary sugar tumor (PEST): a report of four cases. Mod Pathol. 2001; 14(6): 615-22[DOI][PubMed]
  • 29. Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: the past, the present and the future. Virchows Arch. 2008; 452(2): 119-32[DOI][PubMed]
  • 30. Kaiserling E, Krober S, Xiao JC, Schaumburg-Lever G. Angiomyolipoma of the kidney. Immunoreactivity with HMB-45. Light- and electron-microscopic findings. Histopathology. 1994; 25(1): 41-8[DOI][PubMed]
  • 31. Mukai M, Torikata C, Iri H, Tamai S, Sugiura H, Tanaka Y, et al. Crystalloids in angiomyolipoma. 1. A previously unnoticed phenomenon of renal angiomyolipoma occurring at a high frequency. Am J Surg Pathol. 1992; 16(1): 1-10[DOI][PubMed]
  • 32. Sato K, Ueda Y, Tachibana H, Miyazawa K, Chikazawa I, Kaji S, et al. Malignant epithelioid angiomyolipoma of the kidney in a patient with tuberous sclerosis: an autopsy case report with p53 gene mutation analysis. Pathol Res Pract. 2008; 204(10): 771-7[DOI][PubMed]
  • 33. Li J, Zhu M, Wang YL. Malignant epithelioid angiomyolipoma of the kidney with pulmonary metastases and p53 gene mutation. World J Surg Oncol. 2012; 10: 213[DOI][PubMed]
  • 34. Park JH, Lee C, Suh JH, Kim G, Song B, Moon KC. Renal epithelioid angiomyolipoma: Histopathologic review, immunohistochemical evaluation and prognostic significance. Pathol Int. 2016; 66(10): 571-7[DOI][PubMed]
  • 35. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015; 67(5): 913-24[DOI][PubMed]
  • 36. Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013; 49(4): 255-65[DOI][PubMed]
  • 37. Curatolo P, Bombardieri R. Tuberous sclerosis. Handb Clin Neurol. 2008; 87: 129-51[DOI][PubMed]
  • 38. Eijkemans MJ, van der Wal W, Reijnders LJ, Roes KC, van Waalwijk van Doorn-Khosrovani SB, Pelletier C, et al. Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands. Am J Kidney Dis. 2015; 66(4): 638-45[DOI][PubMed]
  • 39. Ramon J, Rimon U, Garniek A, Golan G, Bensaid P, Kitrey ND, et al. Renal angiomyolipoma: long-term results following selective arterial embolization. Eur Urol. 2009; 55(5): 1155-61[DOI][PubMed]
  • 40. Murray TE, Doyle F, Lee M. Transarterial Embolization of Angiomyolipoma: A Systematic Review. J Urol. 2015; 194(3): 635-9[DOI][PubMed]
  • 41. Kothary N, Soulen MC, Clark TW, Wein AJ, Shlansky-Goldberg RD, Crino PB, et al. Renal angiomyolipoma: long-term results after arterial embolization. J Vasc Interv Radiol. 2005; 16(1): 45-50[DOI][PubMed]
  • 42. Matuszewski M, Michajlowski J, Bianek-Bodzak A, Krajka K. Radiofrequency ablation of small symptomatic angiomyolipomas of the kidney: Report of two cases. Pol J Radiol. 2010; 75(3): 68-71[PubMed]
  • 43. Castle SM, Gorbatiy V, Ekwenna O, Young E, Leveillee RJ. Radiofrequency ablation (RFA) therapy for renal angiomyolipoma (AML): an alternative to angio-embolization and nephron-sparing surgery. BJU Int. 2012; 109(3): 384-7[DOI][PubMed]
  • 44. Kang SK, Huang WC, Pandharipande PV, Chandarana H. Solid renal masses: what the numbers tell us. AJR Am J Roentgenol. 2014; 202(6): 1196-206[DOI][PubMed]
  • 45. Zapardiel I, Delafuente-Valero J, Bajo-Arenas JM. Renal angiomyolipoma during pregnancy: review of the literature. Gynecol Obstet Invest. 2011; 72(4): 217-9[DOI][PubMed]
  • 46. Konosu-Fukaya S, Nakamura Y, Fujishima F, Kasajima A, McNamara KM, Takahashi Y, et al. Renal epithelioid angiomyolipoma with malignant features: Histological evaluation and novel immunohistochemical findings. Pathol Int. 2014; 64(3): 133-41[DOI][PubMed]
  • 47. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008; 358(2): 140-51[DOI][PubMed]
  • 48. Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ, Miles D, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One. 2011; 6(9)[DOI][PubMed]
  • 49. Cabrera-Lopez C, Marti T, Catala V, Torres F, Mateu S, Ballarin J, et al. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial. Orphanet J Rare Dis. 2012; 7: 87[DOI][PubMed]
  • 50. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013; 381(9869): 817-24[DOI][PubMed]
  • 51. Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, et al. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Nephrol Dial Transplant. 2014; 29(6): 1203-10[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments